AI-Powered liver test could spot hidden risks in fatty liver patients

NCT ID NCT06344364

Completed Diagnosis Sponsor: PharmaNest, Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at over 1,200 adults with metabolic fatty liver disease (MASLD) to see if a new digital test, called FibroNest Ph-FCS, can predict who will develop serious liver complications. The test uses computer analysis of standard liver biopsy images to measure scarring. If proven accurate, it could give doctors a better tool to identify high-risk patients and guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Digital pathology test (FibroNest Ph-FCS) analyzing liver biopsy images
What this could lead to: If successful, this test could help doctors better predict which MASLD patients are at risk of serious liver problems, enabling earlier intervention.
What could go wrong: This is a retrospective study, not a treatment trial. The test may not be accurate enough in real-world settings or for all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

Contacts and locations

Locations

Fundació de Recerca Clinic Barcelona

Barcelona, Spain
The Chinese University of Hong Kong

Shatin, Hong Kong
University of Seville

Seville, 41004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.